Neuroblastoma (NBL) is an embryonal cancer of the sympathetic nervous system (SNS), which causes 15% of pediatric cancer deaths. High-risk NBL is characterized by N-Myc amplification and segmental chromosomal gains and losses. Owing to limited disease models, the etiology of NBL is largely unknown, including both the cell of origin and the majority of oncogenic drivers. We have established a novel system for studying NBL based on the transformation of neural crest cells (NCCs), the progenitor cells of the SNS, isolated from mouse embryonic day 9.5 trunk neural tube explants. Based on pathology and gene expression analysis, we report the first successful transformation of wild-type NCCs into NBL by enforced expression of N-Myc, to generate phenotypically and molecularly accurate tumors that closely model human MYCN-amplified NBL. Using comparative genomic hybridization, we found that NCC-derived NBL tumors acquired copy number gains and losses that are syntenic to those observed in human MYCNamplified NBL including 17q gain, 2p gain and loss of 1p36. When p53-compromised NCCs were transformed with N-Myc, we generated primitive neuroectodermal tumors with divergent differentiation including osteosarcoma. These subcutaneous tumors were metastatic to regional lymph nodes, liver and lung. Our novel experimental approach accurately models human NBL and establishes a new system with potential to study early stages of NBL oncogenesis, to functionally assess NBL oncogenic drivers and to characterize NBL metastasis.
INTRODUCTION
Neuroblastoma (NBL) is the most common extracranial pediatric solid tumor and is responsible for 15% of pediatric cancer deaths. It is a cancer of the sympathetic nervous system (SNS) with primary lesions found in the sympathetic ganglia and the adrenal medulla. Both clinical observations and treatment approaches suggest that NBL is a cancer caused by impaired development. Patients receive retinoic acid treatment as a standard therapy to promote tumor cell differentiation and a delayed onset of development is a prominent explanation for complete spontaneous regression seen in the 4S category of metastatic NBL. Furthermore, poorly differentiated/undifferentiated histology is an independent indicator of poor outcome for NBL. 1 From these observations, a block in development is thought to contribute to NBL oncogenesis. 2, 3 During development, neural crest cells (NCCs) are the precursor stem cell population that gives rise to neuroblasts, a proliferative post-migratory neural crest population that is a proposed cell of origin for NBL. NCCs are a highly migratory, multipotent cell population specified during neural tube closure that generate a variety of ectodermal and mesodermal tissues including neurons of the SNS, Schwann cells, melanocytes and osteoblasts. 4 NCCs migrate ventrally at mouse embryonic day 9.5 to the dorsal aorta where they receive inductive signals to form sympathetic ganglia or continue to the adrenal anlage to form chromaffin cells of the adrenal medulla. NCCs are the proposed embryonic precursor cell population to multiple pediatric malignancies including NBL, peripheral primitive neuroectodermal tumors, malignant peripheral nerve sheath tumors, craniofacial osteosarcoma, as well as adult malignancies such as melanoma. 3, 5, 6 However, primary NCCs have not been used to model any of these various malignancies.
N-Myc amplification and segmental chromosomal changes are the most frequent genetic alterations in high-risk NBL. However, the oncogenes and tumor suppressors from each of these segmental chromosomal gains and losses have not been defined, making the molecular etiology of this disease not well understood. Therefore, most modeling of the disease in mammalian systems is based on N-Myc overexpression. [7] [8] [9] [10] In this study we establish a system for rapid, functional assessment of candidate oncogenic drivers in a normal genetic background and report the first successful transformation of primary NCCs into NBL by N-Myc overexpression. The resulting tumors both histologically and molecularly recapitulated MYCN-amplified NBL, including acquisition of chromosomal aberrations in regions syntenic to those seen in human N-Myc-amplified NBL. The NCC approach we have established is a promising new tool to assess the functional contribution of candidate oncogenic drivers and to study the role of impaired development in NBL tumorigenesis.
RESULTS AND DISCUSSION
Isolation and characterization of primary NCCs Trunk NCCs migrate ventrally from the neural tube to form sympathetic ganglia and the adrenal medulla. 11 To isolate NCCs, trunk neural tube explants were dissected from 9.5 dpc embryos and cultured for 48 h, to allow NCC migration onto the plate. Isolated NCCs were then assessed by immunofluorescence and found to be uniformly positive for the early neural crest marker Sox10 and the p75 nerve growth factor receptor ( Figure 1a ).
We used quantitative PCR to compare gene expression in isolated NCCs versus adult mouse adrenal gland. As expected, NCCs had significantly higher levels of the neural crest markers Sox10, p75 and Ascl1 than adrenal gland (Figure 1b ), but did not express Phox2B or TH, a marker for differentiated dopaminergic neurons (Figure 1c) . These results indicate the isolated cells are uncommitted NCCs. When cells were cultured in neuronal differentiation media for 1 week, they generated neurons as determined by morphology (Figure 1d ) and the neuronal marker MAP2 (microtubule-associated protein 2) (Figure 1e ). Schwann cells were also generated among the neurons, as determined by GFAP (glial fibrillary acidic protein) immunostaining (Figure 1e ). Both the marker analysis and the lineage commitment study confirmed that we are isolating highly enriched primary NCCs.
Compromised p53 with N-Myc leads to neuroectodermal tumors with divergent differentiation from NCCs Aberrant N-Myc expression is found in NBL and N-Myc overexpression was used to model NBL in the TH-MYCN NBL mouse model; therefore, we tested the capacity of N-Myc to transform NCCs. We used Trp53-compromised NCCs to increase the likelihood of generating tumors with N-Myc transformation, as relatively few cells are isolated per neurotube explant (~3,000 NCCs) and there was no precedent for generating cancers from primary NCCs. To generate p53 compromised NCCs, we crossed p53-null males with p53 heterozygous females and isolated neurotube explants. NCCs pooled from both heterozygous and homozygous p53-null C57Bl/6 embryos were transduced with N-Myc-IRES-GFP retrovirus. 15 The next identifiable cancer type within the tumor mass was osteosarcoma with osteoid secretions and a subset of those osteosarcomas showed chondrocyte differentiation ( Figure 2b , upper right). Additional malignancies that did not express any of the markers tested were also observed. Overall, by immunohistochemistry and pathology review tumors were characterized as primitive neuroectodermal tumors with divergent differentiation. In mice with slower growing tumors we noted macroscopic metastases. The metastases were observed in the lymph nodes, liver and lung, and often showed a mixed morphology similar to the primary tumors with regions of primitive neuroectodermal tumors and osteosarcoma (Figure 2c ), although some lymph node metastases appeared exclusively NBL-like or osteosarcoma ( Figure 2c , insets i and ii, respectively). Although TP53 is not found mutated at NBL diagnosis and rarely mutated at relapse, 49% of relapse patients showed defects in pathways upstream of p53, such as in p14 ARF and MDM2. 17, 18 N-Myc overexpression in p53-compromised NCCs caused complete tumor penetrance and generated multiple cancer types. These results underscore the capacity of NCCs to generate a diverse array of cancer types, which corresponds to their capacity to generate a diverse array of tissues. Although subcutaneous tumors rarely metastasize, this was a salient feature of our neural crest-derived cancers, which recapitulates the highly metastatic nature of human NCC-derived cancers such as NBL and melanoma.
N-Myc transformation of NCCs generates NBL and osteosarcoma
Having established that tumors can be generated in our protocol, we next determined whether N-Myc was sufficient for transformation. NCCs were retrovirally infected within 48 h of isolation with either MSCV-NMyc-GFP or -RFP and cells were injected the next day subcutaneously into the flanks of mice. N-Myc NCCs generated tumors in 8 out of 26 (31%) mice with a broad range of tumor onsets from 52 days to 226 days (Figure 3a) . The histologically assessed N-Myc NCC tumors were either neuronal or osteosarcoma and did not show the mixed morphology observed in N-Myc; p53 mixed NCC tumors ( Figure 3b ). The neuronal tumors ( Figure 3c ) were composed of a highly proliferative homogeneous population with 490% of the cells expressing nuclear Ki67 and diffuse Synaptophysin expression. The tumors were interspersed with neuropil, which indicates a poorly differentiated NBL. TH and MAP2 expression was seen in a scattering of individual cells and Chromogranin A expression was associated with ganglion-like cells adjacent to areas of necrosis. Phox2B, a highly specific and sensitive marker of NBL, was broadly expressed in the tumors. mixed NCC tumors were comparable to dramatically higher expression of N-Myc (Figure 3e ). Based on a pathologist's review of the tumors, they are consistent with a classification of large cell/nucleolar NBL of the poorly differentiated subtype. 16, 21 The large cell/nucleolar NBL subclassification of neuroblastoma is strongly associated with N-Myc amplification and is speculated to be a consequence of N-Myc overexpression. 16, 21 This subtype is also a highly aggressive variant of NBL with very poor outcome that is proposed to be a developmentally immature stem cell-like NBL. 21, 22 The second set of tumors was negative for Synaptophysin, Phox2B, Map2, TH and Chromogranin A. By hematoxylin and eosin staining, the tumors showed features of osteosarcoma with extensive osteoid throughout the tumors and were designated as osteosarcomas (Figure 3b, right) . During craniofacial development, NCC-derived osteoblasts form the bone and cartilage of the face and neck. Mutations in p53 are frequently observed in human osteosarcoma; similarly, we found that the N-Myc osteosarcoma Figure 1 . Cells isolated from trunk neural tube explants are NCCs by marker analysis and differentiation potential. (a) Day 9.5 embryos were isolated and dissected to remove the neural tube from a region caudal to the heart to the most caudal somite. Isolated neural trunks were treated with 1 mg/ml collagenase/dispase for 5 min, while being triturated in a Pasteur pipette. Neural tube explants were cultured in neural crest media (EMEM (Life Technologies, Waltham, MA, USA, 51200-038) with 3% chick embryo extract (US Biologicals, Salem, MA, USA, C3999) and 15% fetal bovine serum (Omega Scientific, Tarzana, CA, USA, FB-02)) on fibronectin-coated plates for 48 h, to allow NCC migration onto the plate before the neural tubes were removed. Immunofluorescence staining on cells isolated from neural tube explants using antibodies to the nerve growth factor receptor p75 (green, EMD Millipore, Billerica, MA, USA, 07-476) and the transcription factor Sox10 (red, ThermoFisher Scientific, Waltham, MA, USA, MAB2864), both markers of early neural crest. The merged image also includes DAPI nuclear staining. Scale bar = 10 μm. Figure 2) . Three Phox2b/ TH-positive, Runx2/Satb2-negative N-Myc NCC tumors were submitted for gene expression analysis using Affymetrix Mouse 2.0 ST arrays (ThermoFisher Scientific, Waltham, MA, USA). Genes found upregulated 42 log ratio over normal adrenal for the mouse NCC-derived NBL were analyzed with the Cancer Cell Line Encyclopedia database using the gene set analysis tool Enrichr. 23, 24 The N-Myc NCC tumors matched human NBL at an average significance of P-value o1 × 10 − 7 (Figure 4a ). When NCCderived NBL were compared with individual NBL cell lines, the NCC-derived NBL tumors best fit with N-Myc amplified NBL with P- 36 were mixed with 100 μl Matrigel (BD Biosciences, San Jose, CA, USA, 356237) and injected subcutaneously on the right flank of 6-to 8-week-old either Nu/Nu mice or C57Bl/6 mice (Charles River, Wilmington, MA, USA). Mice were injected on a rolling basis, to generate sufficient numbers of tumors for further analysis in a nonrandomized, non-blinded manner. Eight Nu/Nu mice (left panel) and six C57Bl/6 mice (middle panel) were each flank injected with N-Myc transduced primary p53 mixed NCCs pooled from p53 +/ − and p53 − / − embryos (middle panel). Four C57Bl/6 mice were flank injected with N-Myc transduced primary p53 +/ − NCCs (right panel). Individual tumor volumes were measured over time as previously described. 36 (b) Formalin-fixed tissue samples were prepared as previously described. To identify commonly upregulated genes that might be important for NBL oncogenesis, we compared the gene expression profile of the N-Myc NCC NBLs with human N-Myc-amplified NBLs. Genes with interspecies gene expression 41 log ratio for mouse and human NBL tumors over normal adrenal were determined (Figure 4c ). Foxm1, Mybl2 (BMYB) and E2f3 are all highly overexpressed in both the human and mouse NBL (Figure 4c) , and are part of a cell cycle regulatory complex. During proliferation, the multi-vulval class B (MuvB) protein complex regulates progressive stages of the cell cycle through coordinated interactions with B-MYB (Mybl2) and forkhead M1 (Foxm1). 25 In
Neuroblastoma (17) Lung (128) Salivary (2) Thyroid (11) CNS (46) Endometrium (16) Ovary (36) Soft Tissue (15) Bone (20) Urinary Tract (15) Stomach (29) Pancreas (16) Esophogus (16) Prostate (6) Breast (48) Skin (46) Liver (21) Biliary Tract (3) Intestinal (31) Hematopoietic (163) Kidney (11) Pleura ( Figure 3) . In addition to the upregulated cell-cycle-associated genes, both human NBL and NCC-derived NBL shared multiple upregulated neural developmental transcription factors (Sox11, Nhlh2, Twist1, Ascl1, Insm2 and Tcf3) that are also important for neural crest development. TCF3 is a bHLH protein that partners with tissuespecific bHLH transcription factors to transactivate target genes and is known to interact with both Twist1 and Ascl1. Phox2b and Ascl1 regulate Hand 1/2 and Gata 2/3, which promote sympathoadrenal differentiation and proliferation. Both Twist1 and Ascl1 are direct transcriptional targets of N-Myc 28, 29 and all three of these transcription factors, along with Nhlh2, have been shown to be important in NBL oncogenesis.
Although direct therapeutic targeting of transcription factors is difficult, their downstream effectors, such as kinases, are potential drug targets. We identified multiple kinases that show shared overexpression between our model and human NBL (Figure 4c and Supplementary Figure 4) . Some of these kinases have already been shown to be promising targets in NBL, including anaplastic lymphoma receptor tyrosine kinase, checkpoint kinase 1 and aurora kinase A. [30] [31] [32] Our data highlights additional kinases that may be important therapeutic targets including cyclin-dependent kinase-1 and PDZ-binding kinase. Inhibitors to cyclin-dependent kinase-1 are currently in clinical trials 33 and PDZ-binding kinase is overexpressed in many cancers and correlates with poor prognosis in various malignancies. Small-molecule inhibitors of PDZ-binding kinase have shown promise in reducing growth of glioblastoma tumors in mice. Our manuscript establishes that it is possible to isolate and ex vivo genetically manipulate NCCs to establish NBL tumors in mice. This more rapid method of generating mouse models of NBL is an important new way to interrogate the genetics of cancer in addition to the more traditionally used strategies of cell lines, xenografts and genetically engineered mouse models. Key challenges for NBL research are establishing the molecular etiology of this disease, defining the contribution of impaired development to NBL oncogenesis and finding tractable therapeutic targets. By successfully transforming primary NCC into NBL, we have created a new tool for investigating these critical questions in NBL research. 
